Nov 07, 2023 / 10:30AM GMT
Ganesh Narayan Nayak - Zydus Lifesciences Limited - COO & Executive Director
(technical difficulty)
For today's call we have Dr. Sharvil Patel Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Arvind Bothra, Senior Vice President, Investor Relations; and Mr. Alok Garg Senior Vice President from the Managing Director's office. Now let me give you a broad overview of the developments during the quarter.
In terms of overall revenues, we registered stable growth of 9% during the quarter. Our Branded Formulations business in India grew in a single high digit after adjusting for impact of NLEM and partly affected by delay in the acute season. The U.S. Formulations business performed on expected lines, driven by a stable base business and supported by new introductions. Our Emerging Markets and Europe Formulations businesses continued growth momentum and delivered double-digit growth.
Our network of regulatory-compliant manufacturing facilities and a resilient supply chain serves as the backbone of our globally -- global business. We remain committed to extend our
Q2 2024 Zydus Lifesciences Ltd Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot